Evaluation of ARB in Anithypertersive Therapy
- VernacularTitle:从LIFE和VALUE试验看ARB的降压地位
- Author:
Ai WANG
;
Guangmin ZENG
;
Zhenping WU
- Publication Type:Journal Article
- Keywords:
Cardiac Cerebral and Vascular Diseases;
Antihypertension;
ARB;
Total mortal
- From:
Journal of Chinese Physician
2002;0(S1):-
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To evaluate the effectiveness of ARB in antihypertensive therapy and judge whether it can also protect cardiovascular. Methods A randomized double-blinded placebo-controlled study was used to survey over ten thousand patients in ARB clinical practices. The primary endpoint was stroke, acute myocardial infarction, heart failure, deadly cardiovascular diseases, total mortal. The results were given comprehensive analysis and statistical processing. Results In LIFE study, ARB was more effective than ?-blockers and ARB had the role of protecting the cardiovascular besides lowering the blood pressure. But the VALUE study showed that ARB was not more effective than Besylate. Conclusion There is no obvious distinction between ARB and the other drugs in reducing the blood pressure.
